Hormone Therapy Can Be Life-Changing—And You Can Start It Sooner Than You Think
By now, you've probably heard the negative messaging around hormone therapy (also known as hormone replacement therapy or HRT). It's dangerous! It causes breast cancer! It'll make you gain weight! Except these are half-truths. Hormone therapy can actually be life-changing for menopausal women—and provide the most benefits, with the lowest risks, for perimenopausal women.
When we talk about hormone therapy, we're typically referring to low doses of estradiol (the primary form of estrogen in your body during your reproductive years) and progesterone. Unlike the hormones commonly found in birth control, these aren't synthetic hormones—they are known as bioidentical hormones, which have the same chemical makeup as the hormones in our body. Hormone therapy is FDA-approved to alleviate symptoms like hot flashes, night sweats, vaginal dryness, painful sex, and recurrent UTIs. It also offers some pretty amazing benefits, such as preserving bone health, improving heart health, and lowering the risk of diabetes. If a woman doesn't have a uterus, then she typically only takes estrogen, but if she does, she takes both estrogen and progesterone to protect the lining of the uterus from excess thickening.
In perimenopause, estrogen and progesterone fluctuate wildly, which can make it a little tricky to find the right dosage (usually you start on the lowest dose and go up based on response, tolerability, and efficacy). This is why ob-gyns will often recommend birth control pills or a progestin IUD—potentially with an added low dose of estradiol—as a first course of action to alleviate symptoms. The birth control can turn off the crazy fluctuating hormones (therefore controlling irregular periods and, in some cases, eliminating them completely). It also provides contraception since you can still get pregnant while in perimenopause.
But for perimenopausal women who haven't had great experiences with birth control, are experiencing bothersome symptoms, and aren't planning to get pregnant, experts agree that hormone therapy can be a good option for them.
'For young people who are having [perimenopausal] symptoms, unless they have an absolute contraindication like breast cancer, the benefits are going to outweigh the risks,' says Jan Shifren, MD, a gynecologist, reproductive endocrinologist, and director of the Mass General Hospital Midlife Women's Health Center. Some other contraindications are a history of coronary heart disease (CHD), stroke, liver disease, estrogen-sensitive cancers, and unexplained vaginal bleeding. 'Once you are in your 50s, then you have to be a little bit more concerned about risks than a young person does.'
For women over 60 who take estrogen and progesterone for more than four years, research has shown there's a slight increase in breast cancer risk—1 out of every 1,000 women—as well as an increased risk of heart disease, stroke, and dementia (more on that in 'The Great Hormone Therapy Comeback' here). To experience the most benefits with the lowest risks, it's ideal to start hormone therapy before you turn 60 or within 10 years of your last period.
That said, you can begin as early as your 30s. In fact, there are young patients with premature ovarian insufficiency (when a woman's ovaries stop working before she's 40) who require hormone therapy much earlier than others going through natural menopause. However, Dr. Shifren says perimenopausal women shouldn't start hormone therapy to prevent symptoms. Rather, they should think of hormone therapy as a potential treatment option for symptoms affecting their quality of life. Determining when to stop taking it, if at all, depends on your goals for the therapy weighed against potential side effects and risks. Make sure to discuss this with a certified menopause practitioner.
Testosterone Enters the Chat
Spoiler alert: Women produce three times more testosterone than estrogen before menopause. Testosterone gradually declines as we age, and that can impact mood, energy level, libido (a.k.a. sex drive), bone health, and muscle mass. As menopause has gone mainstream, some female urologists are advocating that women add testosterone to their hormone therapy regimen. The problem? There are zero FDA-approved testosterone products for women, which makes it difficult for us to access and afford it.
'The role of testosterone is just a lesson in gender bias,' says Kelly Casperson, MD, a urologist. 'Because 100 percent of women will have low testosterone and there's zero FDA-approved products. About 20 percent of men will have low testosterone and there are plenty of FDA-approved products.'
Not all health care practitioners agree that women should be prescribed testosterone, though. Dr. Shifren, a gynecologist, notes that the actual benefit of testosterone above that of a placebo is very small—though she acknowledges a placebo works—and she prefers to get to the root cause of symptoms like low libido.
'Low libido is incredibly common for women, and it's often due to things like fatigue, stress, relationship conflict, depression, anxiety, and painful sex,' she explains. 'It's much easier to write prescriptions for off-label compounded testosterone and send someone on their way. But when you really take a thorough look at their history, you find a lot of things that people can improve to make their lives better.'
Dr. Casperson argues that, placebo effect or not, there isn't harm in prescribing women low-dose testosterone—five milligrams per day in the form of a gel or a cream—if it improves their symptoms and they monitor their levels. (Though it's not recommended to go on T if you can or are planning to get pregnant, as it could affect the baby.) Consult a health care professional to discuss potential side effects and risks.
This story appears in the Summer 2025 issue of Women's Health.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
32 minutes ago
- Medscape
Cardiac Arrest Survival Rises Over Last Two Decades
TOPLINE: While the incidence of cardiac arrest occurring outside the hospital has remained relatively stable, at about 81 per 100,000 person-years, between 2001 and 2020, data show survival rates improved from 14.7% to 18.9% during that period. This improvement corresponded with increased bystander cardiopulmonary resuscitation (CPR), from 55.5% to 73.9%, and the use of early automated external defibrillators, from 2.2% to 10.9%. METHODOLOGY: Researchers conducted a retrospective cohort analysis of 25,118 adults in King County, Washington, who had experienced an out-of-hospital cardiac arrest (OHCA) treated by emergency medical services (EMS) between 2001 and 2020. Of those, 15,994 (63.7%) were men and 9124 were women; the median age was 65 years. Annual incidence calculations were stratified by sex, age group (less than 65 years and 65 years or older), and initial rhythm (shockable, nonshockable). The tesearchers evaluated temporal trends using Poisson regression for incidence and survival to hospital discharge, with resuscitation assessed in five-year groups. TAKEAWAY: Overall survival to hospital discharge improved significantly over time: 14.7% (859 of 5847 individuals) in 2001-2005, 17.4% (1024 of 5885 individuals) in 2006-2010, 19.3% (1232 of 6376 individuals) in 2011-2015, and 18.9% (1322 of 7010 individuals) in 2016-2020 (P < .001 for trend). Survival rates increased substantially for shockable OHCA, from 35% to 47.5%, and for nonshockable OHCA, from 6.4% to 10.1% between the periods spanning 2001-2005 and 2016-2020 (P < .001 for trend). Improvements were observed in both prehospital resuscitation (survival to hospital admission) and in-hospital survival (P < .001 for trend). Community response rose significantly, with bystander CPR increasing from 55.5% to 73.9% and early use of an automated external defibrillator rising from 2.2% to 10.9% (P < .001 for trend). IN PRACTICE: 'Resuscitation outcomes improved over time, a temporal trend that was evident overall and when stratified by presenting arrest rhythm,' the researchers reported. 'The outcome improvements corresponded to improvements in health services such as increase in bystander CPR, AED application before EMS among patients with shockable rhythm, and hospital-based care with targeted temperature management and coronary intervention. The results demonstrate the dynamic nature of OHCA incidence and resuscitation care and outcome that collectively help provide a foundational context to consider strategies of prevention and treatment.' SOURCE: The study was led by Owen McBride, MD, of the Department of Emergency Medicine at the University of Washington in Seattle. It was published online July 16 in JAMA Cardiology. LIMITATIONS: According to the authors, while the study represents a singular regional experience that could affect generalizability, as OHCA incidence and outcome can vary based on geography. Some people who experience OHCA have an emergency response but do not receive resuscitation attempts due to signs of irreversible death or do-not-resuscitate orders, whereas some OHCA events do not receive a 911 medical response. DISCLOSURES: Michael Sayre, MD, reported receiving personal fees from Styker Emergency Response outside the submitted work. Thomas Rea, MD, MPH, reported receiving grants from Philips Medical Funding and the American Heart Association for research independent of the current publication. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
New York Times
33 minutes ago
- New York Times
First Pill for Postpartum Depression Shows Varied Real-World Results
Depression descended on Samantha Cohn about two months after her baby boy was born. He was thriving, but she became convinced she was a terrible mother. 'I felt like I wasn't doing enough, I wasn't doing anything right,' she said. She began to think her son and husband might be better off without her. When the baby was about 5 months old, she tried to take her life with a gun. Ms. Cohn, 30, who lives near Fayetteville, N.C., was hospitalized for weeks and underwent surgeries to repair damage to her jaw, nose, tongue and face. But her postpartum depression remained challenging to treat. The hospital's maternal mental health specialists decided to have her try a medication that had recently become available: the first pill specifically for postpartum depression. Clinical trials had found that the drug, zuranolone, marketed as Zurzuvae and taken daily for 14 days, can ease symptoms for some women in as little as three days, while general antidepressants can take weeks. For Ms. Cohn, its impact was swift and striking. On her fourth day of taking it, she said she suddenly 'felt so much clarity in my head, like I didn't have nagging thoughts about not being good enough.' Now, a year and a half after the drug became available, thousands of women have tried it, and their experiences have run the gamut. For some, symptoms improved remarkably. Others described a modest benefit that didn't last or said their depression persisted. And others didn't complete the two-week regimen because profound drowsiness, a common side effect of the drug, interfered with their ability to care for their babies or to fulfill other responsibilities. One in eight women in the United States experiences depression during pregnancy or in the year after giving birth, the Centers for Disease Control and Prevention estimates, and effective treatments are crucially needed. While the fast-acting pill shows promise, doctors say the challenge now is to determine which patients will benefit and why some don't. Clinical trials of the drug found that postpartum depression improved in about 60 percent of patients. 'It's not everyone,' Dr. Samantha Meltzer-Brody, a leader of the trials and director of the Center for Women's Mood Disorders at the University of North Carolina at Chapel Hill, said at a National Institutes of Health conference. 'So, what is it about the people that are going to respond versus those that don't?' Stacey, 42, of San Diego, who asked to be identified by her first name to protect her privacy, said Zurzuvae made her 'so tired' that after several days of taking it, 'I just felt like a zombie.' 'I actually felt more depressed while I was on it,' she said. To address Stacey's response to the medication, Dr. Alison Reminick, director of women's reproductive mental health at the University of California, San Diego, advised her to take half doses for the rest of the 14 days. But Stacey said she stopped Zurzuvae altogether, halfway through the regimen, because the sluggishness made it difficult to care for her baby. 'The medication is incredibly sedating,' Dr. Reminick said. 'There's a warning on the box. They can't drive for 12 hours after taking it and they can't really take care of their children without help.' Yet, some patients don't experience sedation and others welcome it because it helps them get much-needed sleep and feel less overwhelmed, said doctors who prescribe Zurzuvae. The week after Ms. Cohn started taking Zurzuvae, the turnaround of her symptoms was so obvious that she was discharged from the hospital. 'She had a really nice improvement of her postpartum depression with that medicine,' said Dr. Riah Patterson, a psychiatrist at U.N.C. Chapel Hill. Ms. Cohn finished the 14-day regimen at home and attended intensive outpatient therapy for months. Now, she has gone back to work as a tattoo artist, and she said that with weekly therapy and an anxiety medication, she is managing the aftermath of the crisis, including undergoing additional surgeries. 'I'm just excited to get a little bit closer to really being me again,' she said. She no longer feels anxious about her parenting ability and enjoys playing with her son and taking him to places like the local children's museum. 'He makes everything worth pushing through.' Importance of quick intervention Zurzuvae is a synthetic version of a steroid called allopregnanolone that originates in the brain. The theory behind the medication is that perinatal depression often arises as hormones that surge in pregnancy plummet during childbirth. Some women seem particularly sensitive to that sudden drop-off, which also lowers levels of the steroid, Dr. Meltzer-Brody said. Zurzuvae can be taken with other antidepressants, and, since it is prescribed for only a single 14-day course, some doctors use it as an adjunct or bridge to ease severe symptoms before longer-term use of antidepressants. Some patients who are breastfeeding have declined to take the drug because its penetration of breast milk has not yet been studied. Doctors said it is likely safe, but if patients are concerned, they might pump two weeks' worth of milk before starting Zurzuvae. Initial logistical hurdles in obtaining Zurzuvae frustrated doctors who said the delays undermined the purpose of a quick-acting medication. Some insurers initially set strict conditions for covering the drug, which has a list price of $15,900. Doctors said some insurers required patients to try other antidepressants first or to obtain prescriptions from psychiatrists, steps that went beyond the F.D.A. requirements for Zurzuvae. Joy Burkhard, chief executive of the Policy Center for Maternal Mental Health, said most insurers and Medicaid no longer have such barriers, but a few still require extra steps. Zurzuvae is not available in retail pharmacies, only specialty pharmacies that require patients to take various measures to validate insurance and delivery information, according to a spokeswoman for the drug's manufacturer, Sage Therapeutics, which markets Zurzuvae in partnership with Biogen. Chris Benecchi, the chief operating officer of Sage, which is expected to be acquired by Supernus Pharmaceuticals later this year, said Sage had worked to resolve logistical issues and prescriptions had increased. More than 10,000 orders have been sent to patients so far, Sage said, adding that about 80 percent of the prescriptions were issued by obstetrician-gynecologists, Sage said. 'The majority of patients are able to get the medication within days,' Mr. Benecchi said, adding that if patients encounter delays, Sage will ship Zurzuvae directly 'as rapidly as possible.' Quick access is crucial, doctors say. Hannah Ginther was hospitalized for a week last summer at U.N.C. Chapel Hill for symptoms that included obsessively worrying that her second child, then 10 months old, had a neurological disorder, even though doctors said the baby did not. 'I just couldn't get out of that loop of jumping to worst-case-scenario,' Ms. Ginther, 36, said at her home in Wilmington, N.C. 'I would throw up. I struggled to get out of bed, struggled to do basic, daily-living things.' When she was discharged from the hospital, doctors prescribed Zurzuvae, but her insurance rejected coverage, saying she would qualify only if she had developed postpartum depression in her last trimester of pregnancy, or within four weeks after childbirth, Dr. Patterson said. Ultimately, the hospital appealed to Sage, which sent the drug to Ms. Ginther at no cost. But the insurance hiccups had caused a two-week delay, during which, Ms. Ginther said, her symptoms 'spiraled again.' She was rehospitalized for nine days. Dr. Julia Riddle, a psychiatrist at U.N.C. Chapel Hill, said the second hospitalization might have been avoided if the Zurzuvae had arrived sooner. By the time it reached Ms. Ginther, she had been stabilized with other medications and intensive therapy. She said Zurzuvae didn't add much, except possibly further improving her mood and sleep. 'I think if we had been able to have access to Zurzuvae sooner, it would have shortened some of the pain, but they were able to find other medications that helped me,' Ms. Ginther said. She has since reduced her workload and continues taking Prozac. She has no intrusive thoughts and is 'doing much better,' she said. Effective for some, but not all As doctors try to determine which patients Zurzuvae can help, Jenny Sharma's experience illustrates the complexity. Ms. Sharma, 43, of San Diego, had a history of depression, especially linked to menstruation, but it was not as severe as the depression she experienced after giving birth in August 2023. Several months later, she began feeling suicidal and she said she also had 'homicidal thoughts toward the baby,' vivid and terrifying images. She sought help from Dr. Reminick's program, trying different medications over several months. While taking Zurzuvae, her symptoms improved. 'I felt wonderful,' she said. Dr. Reminick said Ms. Sharma's response to Zurzuvae was 'the best I've ever seen her.' But, she said, about 11 days into the 14-day regimen, Ms. Sharma started speaking haltingly and appeared to have 'cognitive difficulties, whole body shaking and twitching, confusion and dizziness.' Dr. Reminick said it was unclear whether those symptoms were linked to Zurzuvae or to another medication. Overall, she said she considered Zurzuvae a 'good fit' for Ms. Sharma, but her improvement didn't last. 'About a month later, my symptoms all came raging back,' Ms. Sharma said. Afraid that she would harm her baby, she visited an emergency room and then had several psychiatric hospitalizations and electroconvulsive therapy. Eventually, with other medications and some supplements, her mental health stabilized, although she occasionally experiences brief periods of depressive thoughts, she said. In clinical trials, patients helped by Zurzuvae continued doing well 45 days later. About half of those who took Zurzuvae were considered to be in remission. Dr. Riddle is following patients to see if the benefit can last longer. 'No one's illness is exactly the same,' Dr. Riddle said. So far 'no one has said they'd never take it again, it's just varying levels of how helpful it was.' For Kara Fiscus, 37, of Sacramento, the benefit has lasted more than a year. Her depression began about five months after her son was born in May 2023. She felt so overwhelmed that she wrote in her journal, 'I should kill myself.' Ms. Fiscus, a former N.F.L. cheerleader, said she had been prepared for some depression because she had mental health challenges in her teens and 20s. But her postpartum symptoms, especially anxiety over not producing enough breast milk and about her baby's weight, were worse than anything she had experienced. 'When you have a child and you're not able to meet their needs, it's no longer that your life is not meeting your own standards — you feel like an impediment to other people,' she said. Her obstetrician, Dr. Hailey MacNear, prescribed Zoloft and, when that didn't work, Prozac. But before enough time had passed to know whether Prozac could help, Ms. Fiscus began planning to take her own life. After calling Dr. MacNear, she entered a partial hospitalization program followed by intensive outpatient treatment, but continued thinking of ending her life. Then, Dr. MacNear prescribed Zurzuvae, which had just become available. On the third day, Ms. Fiscus realized, ''Oh my god, I haven't thought about killing myself in at least 20 minutes.'' And 'by Day 7, I was feeling really, really great.' Dr. MacNear said that not every patient experienced similar improvement and that some declined to try it because of the sedative effects. But she said Ms. Fiscus called her and 'cried with relief' after taking it. While taking Zurzuvae, Ms. Fiscus continued breastfeeding and returned to work, eventually becoming an official at a nonprofit. She still takes Prozac, but credits Zurzuvae with ending her thoughts of self-harm. She even saved the box. 'It's a comfort seeing it,' she said. 'There's hope in that box.' If you are having thoughts of suicide, call or text 988 to reach a lifeline for help, or go to If you or someone you know is struggling with a perinatal mental health condition like postpartum depression, call the Postpartum Support International Helpline (1-800-944-4773) or go to
Yahoo
35 minutes ago
- Yahoo
RFK Jr.'s choice of attire while hiking in Arizona sparks online chatter
The Brief Secretary of Health and Human Services Robert F. Kennedy, Jr. was seen hiking Camelback Mountain in Phoenix on July 19. The hike sparked online chatter, however, as RFK Jr. was seen hiking in jeans, during a normally hot part of the year for Arizona. It is not known if RFK Jr. was in Phoenix for business or for vacation. PHOENIX - Secretary of Health and Human Services Robert F. Kennedy Jr. was spotted hiking Camelback Mountain over the weekend, and what he was wearing is causing some chatter on the internet. What we know "It really made my day, it was really cool," said Matt Larson, who met Kennedy on the trail. It's a meeting Larson said he will never forget. He said he was hiking Camelback Mountain when someone caught his eye. "I noticed what appeared to be a senior," said Larson. "I didn't have my contacts in, so I couldn't see very well, but he had a group of people around him, and they were very close to him, and I thought he must have had an issue, like fall or a heatstroke." As they were walking down the Echo side of the trail, Larson walked up to offer some water. "When I got close, I noticed the older person was talking politics to the people rescuing him," Larson recounted. "I remember thinking: wow, leave it to an old white, boomer guy to be talking politics on his potential deathbed." Then, the pieces started falling together. "At that point I was close enough, where I recognized him, and I was like 'woah. Is that [RFK Jr.]?" Larson said. Larson then asked the men with the Health Secretary, which he then realized were security, for a selfie. Larson said Kennedy himself snapped the photo. "It was about 92°, I think, temperature wise, at that point, so very impressive for him to have done that at his age," Larson said. Hiker Deric Keller, who took a selfie with Kennedy and a friend, said they met him around 6:00 a.m. when he first started up the trail. They said the weather wasn't too bad, and that they even chatted with him for a few minutes. Dig deeper Online, Kennedy posted a photo on his X page at the summit, garnering some admiration and some criticism for both the jeans attire and hiking in the heat. "I remember thinking, 'that wouldn't be my choice of hiking apparel in this weather,' but you know, kinda a generational thing," said Larson. "It's what my dad would have probably hiked in, so makes sense." Larson, however, added that "it is pretty risky to be hiking if you're not acclimated to our weather in the heat." Larson said politics aside, he's still in disbelief over the chance encounter on the hard hike. "I let a few of my friends know — I don't know if you know this, but RFK is actually in better shape than you," he said. The other side The Department of Health and Human Services communications team has not yet confirmed if Kennedy was in Arizona for business, or if he was on vacation. Solve the daily Crossword
